Auxilium Pharmaceuticals, Inc.
) reported a first quarter loss of 4 cents per share, well below
the year-ago loss of 25 cents and the Zacks Consensus Estimate of a
loss of 12 cents. Revenues, which increased 26% to $73.6 million,
were above the Zacks Consensus Estimate of $71 million.
Quarter in Detail
During the reported quarter, total Testim sales increased 27% to
$58.7 million. Testim revenues in the U.S. were $57.9 million.
Auxilium Pharma expects Testim revenues of $215 - $225 million
in 2012, up from $207.9 million in 2011. The company intends to
focus on payors, physicians, and patients with Testim in 2012.
Testim, however, is facing a patent challenge from Watson
Meanwhile, Xiaflex sales increased 22% to $14.9 million,
including contract and ex-U.S. revenues. U.S. revenues increased
46% to $12.6 million. In addition to the U.S., Xiaflex is available
in several other countries including the U.K. (trade name Xiapex),
Germany, Austria, Denmark, Finland, Norway and Sweden.
Auxilium Pharma is working on creating and increasing awareness
among physicians and patients about Xiaflex. The company continues
to present data on the clinical profile of Xiaflex. Besides this, a
direct response TV campaign is ongoing in select cities.
While the January 2012 implementation of a permanent CPT code
could help smoothen the reimbursement process, we expect the
implementation of the CPT code to have a modest impact on Xiaflex
Auxilium Pharma is working on expanding Xiaflex' label. The
company is currently conducting phase III studies (IMPRESS) with
Xiaflex for Peyronie's disease. Top-line results from the phase III
program should be out in June 2012. Positive results would allow
the company to file for approval by year end.
Auxilium Pharma initiated a phase Ib study in Jan 2012 for the
treatment of cellulite (edematous fibrosclerotic panniculopathy) -
top-line results are expected in late 2012. Xiaflex is currently in
a phase IIa study for the treatment of frozen shoulder syndrome
with top-line results expected in the first half of 2013.
BioSpecifics Technologies Corp.
), Auxilium Pharma's licensor, has initiated a phase II study in
canine lipoma with results expected in the first half of 2013.
Research and development expenses for the reported quarter
declined 24.1% to $12 million due to lower spending on the
Peyronie's studies. Selling, general and administrative expenses
increased 8.6% to $46.9 million mainly due to higher spending on
Xiaflex and direct to consumer advertising.
Neutral on Auxilium Pharma
We currently have a Neutral recommendation on Auxilium Pharma,
which carries a Zacks #3 Rank (short-term 'Hold' rating). Although
Testim has been performing well, tough competition could limit the
ultimate potential of the drug. Given the eventual slowdown in
Testim growth, Auxilium Pharma's future relies heavily on Xiaflex.
However, Xiaflex' performance continues to lag expectations. With
Auxilium Pharma working on driving sales of the product, we expect
investor focus to remain on the successful commercialization of
Xiaflex/Xiapex, and label expansion of the product for additional
indications. An important event is coming up in June when the
company expects to present data on the Peyronie's indication.
AUXILIUM PHARMA (AUXL): Free Stock Analysis
BIOSPECIFICS TE (BSTC): Free Stock Analysis
To read this article on Zacks.com click here.